Structural insight into the bulge-containing KRAS oncogene promoter G-quadruplex bound to berberine and coptisine

Kai-Bo Wang1,3, Yushuang Liu1,3, Jinzhu Li1, Chengmei Xiao1, Yingying Wang1, Wei Gu2, Yipu Li1, Yuan-Zheng Xia1, Tingdong Yan2, Ming-Hua Yang1 & Ling-Yi Kong1

KRAS is one of the most highly mutated oncoproteins, which is overexpressed in various human cancers and implicated in poor survival. The G-quadruplex formed in KRAS oncogene promoter (KRAS-G4) is a transcriptional modulator and amenable to small molecule targeting. However, no available KRAS-G4-ligand complex structure has yet been determined, which seriously hinders the structure-based rational design of KRAS-G4 targeting drugs. In this study, we report the NMR solution structures of a bulge-containing KRAS-G4 bound to berberine and coptisine, respectively. The determined complex structure shows a 2:1 binding stoichiometry with each compound recruiting the adjacent flakcing adenine residue to form a “quasi-triad plane” that stacks over the two external G-tetrads. The binding involves both π-stacking and electrostatic interactions. Moreover, berberine and coptisine significantly lowered the KRAS mRNA levels in cancer cells. Our study thus provides molecular details of ligand interactions with KRAS-G4 and is beneficial for the design of specific KRAS-G4-interactive drugs.

KRAS is justifiably renowned as one of the most highly mutated oncogenes in human cancers and implicated in poor survival, particularly in pancreatic (~95%), colorectal (~41%), and lung (~32%) cancers1. The KRAS protein functions as a small switch signaling GTPase that toggles between an inactive, guanosine-diphosphate (GDP)-bound state and an active, guanosine-triphosphate (GTP)-bound form1. Mutations of KRAS impair its ability to hydrolyze GTP and result in abnormally high levels of GTP-bound KRAS, which lead to the continuous activation of KRAS signaling pathways and uncontrolled cell proliferation, migration, transformation, and survival1,2. Although KRAS is a highly pursued therapeutic target, direct inhibition of mutant KRAS oncoprotein has proven to be challenging in precision oncology for nearly 40 years1. The high intracellular GTP/GDP concentration and their picomolar binding affinity to the KRAS, coupled with the lack of small-molecule binding pockets on the surface of KRAS oncoprotein, lead to a long-standing notion that mutant KRAS is “undruggable”1,4-6. Encouragingly, recent advances in medicinal chemistry have discovered an allele-specific KRAS(G12C) covalent inhibitor, sotorasib (AMG-510), that showed clinical benefit for cancer patients and was conditionally approved by the FDA in 20217-9. However, the KRAS(G12C) only covers a small proportion of KRAS mutations, which were found in ~13% of lung adenocarcinomas, 3% of colorectal cancer, and at a lower frequency in other cancers (less than 1% in pancreatic cancer)1-4,6. Additionally, the diverse and high-frequency acquired resistances further limit the efficacy of KRAS(G12C) treatment10-12. Furthermore, the amplification of wild-type KRAS has been a secondary means for KRAS activation across a number of human cancers11,12. Therefore, it is essential to develop new types of KRAS signaling inhibitors.

Received: 21 March 2022
Accepted: 30 September 2022
Published online: 12 October 2022

1 Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China. 2 School of Life Sciences, Shanghai University, Shanghai 200444, China. 3 These authors contributed equally: Kai-Bo Wang, Yushuang Liu. E-mail: kbwang@cpu.edu.cn; cpu_lykong@126.com
G-quadruplexes (G4s) are unique DNA secondary structures that consist of the stacking of Hoogsteen hydrogen-bonded multiple G-tetrads, which are stabilized by the coordination of K⁺ or Na⁺. The human genomic DNA has lots of G4-forming motifs while endogenous G4 formation is substantially associated with highly transcribed genes. DNA G4 structures are extremely concentrated in the key regulation region of gene promoters implicated in cancer and neurodegenerative disorders. The dynamic formation of DNA G4s in live human cells is cell-cycle-dependent, which can be trapped in the folded states by G4-specific small molecules for gene expression inhibition. G4 structures have thus emerged as distinct DNA targets for cancer therapy, especially as alternative strategies for those "undruggable" proteins, such as MYC and KRAS.

The promoter region of the human KRAS oncogene has a critical GC-rich nucleosome hypersensitive element (NHE), which can form a DNA G4 structure (KRAS-G4). KRAS-G4 has shown to be a transcriptional modulator by interplaying with several nuclear proteins, which is amenable to small-molecule targeting. Small molecules can compete with nuclear proteins to bind the KRAS-G4 for KRAS gene expression inhibition. To date, a number of KRAS-G4 interactive small molecules (ligands) have been reported, together with several types of free KRAS-G4 structures. However, no available KRAS-G4–ligand complexes have yet been determined, which seriously hinders the structure-based rational design of KRAS-G4 targeting drugs. Therefore, much effort is needed to find suitable KRAS-G4 binding ligands and to determine their complex structures.

Natural products have long been a trove of structurally diverse compounds and an important source of anticancer drugs. Notably, we have recently found that several antitumor alkaloids could effectively bind to DNA G4s, presenting a new mechanism of action for anticancer drug development. Among them, berberine and its derivatives have attracted our particular attention as they have diverse antimicrobial activities, and present a unique natural skeleton to the structure-based rational design of KRAS-G4–ligand complexes. Moreover, a small proportion of DMSO in samples does not affect the NMR spectra quality, as shown in Fig. 1c and Supplementary Figs. 2 and 3.

In the current study, we firstly determined the NMR solution structure of a bulge-containing KRAS-G4 using a Pu24m1 DNA sequence, which has the critical 2-3 wild-type residues on both the 5′- and 3′-end flankings, the key elements for specific ligand recognition and selectivity. With the obtained KRAS-G4 model system, we could the obtained KRAS-G4 model system, we could determine that alkaldoids, berberine (BER) and coptisine (COP), could strongly bind and stabilize the KRAS-G4 by using various NMR, CD, and fluorescence experiments. We then determined the atom-level NMR solution structures of KRAS-G4 in complex with BER and COP, respectively. The resolved complex structures elucidate the detailed features for the specific recognition of the KRAS-G4 by ligands and provide a model system for further developing more potent KRAS-G4 targeting drugs. Furthermore, berberine and coptisine significantly stalled the Taq DNA polymerase synthesis of the complementary strand DNAs and lowered the KRAS mRNA levels in cancer cells.

**Results**

**Berberine and coptisine strongly bind and stabilize the KRAS oncogene promoter G4**

The NHE of the KRAS oncogene promoter sequence, namely Pu34 (Fig. 1a), has multiple G-rich tracts, which can form two distinct G4s by using different G-tracts, namely KRAS1234 and KRAS1235 G4s (Fig. 1a and Supplementary Fig. 1). Both of these two types of G4s have been demonstrated to be implicated in nuclear protein interactions for KRAS oncogene regulation and enable small molecule targeting. We focused on the KRAS1234, as G4 with shorter loop lengths is more preferred. Although the solution structure of KRAS1234 G4 (22R, Fig. 1a) has been determined, the critical element for specific ligand recognition is missing in the 5′-end site, as only an adenine residue is available for the binding pocket formation. The flanking residues have been well documented to be critical for G4 formation and specific ligand recognition. We thus used the Pu24m1 DNA sequence that contains the wild-type TGA residues in the 5′-flanking to better mimic the wild-type KRAS promoter G4 (for convenience, the KRAS-G4 refers to Pu24m1 DNA afterward).

Berberine and coptisine (Fig. 1b) to the Pu24m1 DNA sequence using the 1H-NMR titration experiments in a K⁺-containing solution. The free Pu24m1 shows 12 imino proton peaks corresponding to three stacked G-tetrads (Fig. 1c). Upon individual addition of berberine and coptisine, almost all imino proton resonances of the free KRAS-G4 are upfield shifted, revealing binding of one compound at each outer G-tetrad through end-stacking interactions (Fig. 1c). The binding appears to be in an intermediate-to-fast exchange rate on the NMR time scale because the broadening imino proton peaks are shown at a lower drug ratio of 1:1 and the sharpening at higher drug ratio of 2:1 and 3:1. Notably, a new set of 12 distinct protons are emerged after berberine and coptisine addition, respectively, suggesting the formation of one dominant conformation of the ligand–KRAS-G4 complexes. Moreover, a small proportion of DMSO in samples does not affect the NMR spectra quality, as shown in Fig. 1c and Supplementary Figs. 2 and 3.

The binding activity of the two isoquinoline alkaloids to the KRAS-G4 was further investigated by CD, EMSA, and fluorescence experiments. The Pu24m1 sequence adopts a parallel G4 topology that is the same as its shorter 22R sequence, as shown by its characteristic CD spectra with a positive band at ca. 264 nm and a negative band at around 242 nm (Figs. 1a and 2a). Upon the respective addition of two isoquinoline alkaloids, the parallel KRAS-G4 topology was maintained with enhanced CD bands at 264 nm (Fig. 2a). BER and COP increased the thermal stability of KRAS-G4 by 15 and 19 °C at 2 equivalents, respectively (Fig. 2). Meanwhile, a much smaller Tm change was shown from 2 to 4 equivalents of drug addition, suggesting two dominant binding sites of KRAS-G4 for BER and COP. The 2:1 binding stoichiometry was further corroborated in the NMR titration experiment because only minor changes were observed for the imino protons from 2 to 3 ligand equivalents, where the G15-III (Fig. 1c) is clearly seen at 3 ligand equivalents. Notably, a ligand:DNA ratio higher than its binding affinity of two isoquinoline alkaloids to the KRAS-G4 was determined by a fluorescence-based binding assay. Preformed free KRAS-G4 DNA was gradually titrated to a drug solution with a fixed concentration and the induced fluorescence signal was recorded to obtain the dissociation constant (Kd) value (Fig. 2b). The determined Kd values are 0.55 μM and 0.50 μM for berberine and coptisine, respectively (Fig. 2c). Moreover, the KRAS-G4 in complex with berberine and coptisine was monomeric, as shown by the native EMSA gel (Supplementary Fig. 4). Overall, the above data showed that berberine and coptisine strongly bind and stabilize the KRAS-G4 by the formation of well-defined complex structures.
formed at the ligand ratio of 2 or 3, with 12 new emerging imino proton peaks (Fig.1 and Supplementary Figs. 7 and 8). In contrast, the compounds did not show specific binding to telomeric G4s as the ligand–G4 complex structures did not show 12 well-defined imino proton peaks (Supplementary Figs. 9 and 10).

NMR solution structure determination of the wild-type bulge-containing KRAS-G4

We first determined the high-resolution NMR structure of the free KRAS-G4 in the K+ solution, which has a unique T-bulge. The Pu24m1 DNA sequence forms a stable three G-tetrad stacked G4 as shown by 12 well-defined imino proton resonances in the 1D $^1$H-NMR spectrum that is suitable for structure determination (Fig.1c and Supplementary Fig. 14). A set of 2D NMR spectra, including NOESY, DQF-COSY, and HSQC experiments, at different temperatures and mixing times were collected (Fig.3 and Supplementary Figs. 15 and 16). All imino, aromatic, and sugar resonances of KRAS-G4 were assigned using standard strategies and referring to the reported 22R DNA assignment as both sequences have the same 3’-end flanking residues (Supplementary Table S2). The three G-tetrad planes are determined as G4-G8-G13-G20, G5-G9-G14-G21, and G6-G11-G15-G22, which are the same as the 22R G4 with a unique T-bulge (Figs.1b and 3). All DNA residues adopt anti-glycosidic torsion angles as shown by their medium intensities of H$_1$′-H6/H8 NOE cross-peaks and the corresponding down-field C6/C8 chemical shifts (Fig.3 and Supplementary Table 2).

The high-resolution NMR solution structure of the KRAS-G4 was thus determined using restrained molecular dynamics (MD) simulations based on the distance information extracted from the NOESY experiments (Table 1 and Supplementary Tables S2–S5). A total of 745 NOE-derived distances, 48 H-bond, and 24 torsion-angle restraints were used for the simulations. The obtained final ten lowest energy structures were well-converged with a heavy atom root-mean-square deviation (RMSD) of 0.58 ± 0.21 and 0.71 ± 0.21 Å for the G-tetrad core and all residues, respectively (Fig. 4a and Table 1).

The determined parallel KRAS-G4 in the K+ solution shows several distinct features compared to the reported 22-RT G4, especially for...
Nevertheless, the A-T base pair is not observed in the 22-RT G6H1 (Figs. 3, 5a, Supplementary Figs. 12a, and 16, and Supplementary tetrad plane, which is supported by NOE cross-peaks of A23H8 to the 3 ′-end site, the bulge residue T10 is recruited by the Watson–Crick edges point towards opposite grooves (Fig. 5a and Supplementary Fig. 11a). This arrangement is quite similar to the recently determined MYC-G4 with the same TGA flanking residues.29 In the 3′-end site, the bulge residue T10 is recruited by the flanking residue A20 and forms a Watson–Crick base pair that stacks on the 3′-tetrad plane, which is supported by NOE cross-peaks of A23H8 to G22H8, of A23H2 to G22H1, G6H1, G6H8, and T10Me, and of T10H1′ to G6H1′ (Figs. 3, 5a, Supplementary Figs. 12a, and 16, and Supplementary Table 4). Nevertheless, the A-T base pair is not observed in the 22-RT G4 although the same DNA residues are involved.31 Moreover, the 4-nucleotide propeller loop is mostly disordered in the 22-RT G4, whereas it now forms a well-defined structured conformation by constructing an ingenious A16-A19-T18 base stacking organization, which is connected by an A17 linker (Figs. 4a, 5a, and Supplementary Fig. 13a). This unique loop structure is well supported by key NOE contacts of A19H8 to A16H8, A17H8, and T18H6, of A16H8 to A17H8, and of T18Me to A17H8 (Supplementary Fig. 16 and Supplementary Table 5). Overall, the DNA backbone of the 4-nucleotide loop is turned outside and electrostatic repulsions between the negatively charged loop phosphates and the G-tetrad core are minimized by the loop’s central position (Figs. 4a and 5a). Further, the solvent exposure of the loop residues is reduced by extensive base stacking interaction.

**NMR solution structure determination of the 2:1 berberine–KRAS-G4 complex**

The high quality of the 1H-NMR titration data indicated that a well-defined berberine-KRAS-G4 complex is formed, which is feasible for structure determination (Fig. 1c and Supplementary Fig. 14). Therefore, various 2D NMR spectra of the berberine-KRAS-G4 complex were collected, including HSQC, NOESY, and DQF-COSY (Supplementary Figs. 17–21). Similar NOE cross-peak fingerprints were observed between the free KRAS-G4 and its complex with berberine (Fig. 3, Supplementary Figs. 16, 20, and 21). Complete proton resonances were thus assigned with the aid of the free KRAS-G4 spectra assignment (Supplementary Table 6). Protons of free and bound berberine were determined using 1D and 2D NMR spectra (Supplementary Figs. 19, 27, 29 and Supplementary Table 16). The parallel topology and same G-tetrad organization were maintained in the berberine-KRAS-G4 complex compared to the free KRAS-G4 (Figs. 1a and 4). The largest chemical shift difference (Δδ) values were obtained for the HI protons of the 5′- and 3′-end G-tetrad guanines (Supplementary Fig. 31). Moreover, much larger ΔTm values are shown for the flanking residues than the three-loop residues (Supplementary Fig. 32), suggesting that berberine stacks on the two outer G-tetrads.

Numerous inter- and intramolecular NOEs were obtained, which clearly defined the berberine binding sites and the overall complex structures (Fig. 6, Supplementary Figs. 18–21, Table 1, and Supplementary Tables 7–10). The atom-level NMR solution structure of the 2:1 berberine–KRAS-G4 binary complex was then determined using MD simulations. A total of 728 NOE-derived distance restraints were used for the structural calculation (Table 1 and Supplementary Tables 7–10). The binding sites of the berberine at both outer G-tetrads are well-defined and supported by 37 berberine-DNA intermolecular NOE restraints (Figs. 4b, 5b, and 6, Supplementary Table 7). The final ten lowest energy structures are well-converged and show an RMSD of 0.73 ± 0.16 Å for all residues (Fig. 4b, Table 1).

The NMR solution structure shows that the berberine binding induces significant rearrangement for both the 5′-end and 3′-end capping structures (Fig. 5, Supplementary Figs. 11 and 12). At 5′-end, berberine recruits A3 to form a “quasi-triad plan” that stacks over the 5′-end G-tetrad. Compared to the free KRAS-G4, A3 is flipped and the
The cross-peak assigned to the minor species is labeled in blue. c H6 – C6/H8 – C8 cross-peaks of all bases (black label) and the adenine H2-C2 contacts (red label) with assignments for the Pu24m1 DNA by HSQC experiments. d The assigned three G-tetrad planes of KRAS-G4 by NMR experiments. Conditions: 1.5 mM DNA, pH 7, 50 mM K+ solution, 25 °C, DMSO-d6 < 3.5%.

**Fig. 3 | 2D NMR spectra of the free KRAS-G4.** a The H1–H8 and H1–H8 regions, and b H1’–H6/H8 region from the 2D-NOESY spectra of Pu24m1 DNA in H2O with sequential assignment pathway. Missing connectivity is marked with red asterisks. The cross-peak assigned to the minor species is labeled in blue. c H6 – C6/H8 – C8 cross-peaks of all bases (black label) and the adenine H2-C2 contacts (red label) with assignments for the Pu24m1 DNA by HSQC experiments. d The assigned three G-tetrad planes of KRAS-G4 by NMR experiments. Conditions: 1.5 mM DNA, pH 7, 50 mM K+ solution, 25 °C, DMSO-d6 < 3.5%.
The same G-tetrad core was obtained compared to the free KRAS-G4 with G-tracts orientation parallel to each other (Figs. 1a and 4c). The larger Δδ values are shown for the flanking residues and the outer G-tetrad guanines (Supplementary Figs. 33, 34), suggesting that coptisine stacks above the two outer G-tetrads. NMR solution structures of the 2:1 coptisine-KRAS-G4 binary complex were thus solved by NOE-restrained MD simulations (Fig. 6, Supplementary Figs. 11 and 12, Table 1, and Supplementary Tables 11–15). The ten lowest-energy complex structures are presented in Fig. 4c and the RMSD values are shown in Table 1.

The overall structure of the coptisine-KRAS-G4 complex is almost identical to that of the berberine-KRAS-G4 complex (Figs. 4, 5, and Supplementary Figs. 11–13). A similar A-coptisine plane is formed on both the 5′-end and 3′-end capping structures, as well as potential electrostatic interactions between the positively charged CopN7 and the negatively polarized outer tetrad-guanine carbonyl groups. In both the 5′-end and 3′-end complexes, BerN7 and CopN7 are positioned over the central channel above the outer G-tetrad for potential electrostatic interactions. Notably, while the 3′-end sites of the two complexes are indistinguishable, the 5′-end sites differ as the A3:coptisine pair is stabilized by a potential H-bond, as supported by the observation of NOE cross-peaks between coptisine protons and A3H2 (Fig. 5c, Supplementary Table 12). By contrast, the proposed H-bond is weaker in the case of the A3:berberine pair, since the rotatable OCH3 group is

**Table 1 | NMR restraints and structural statistics for the free KRAS-G4 and its complex with berberine and coptisine**

|                      | KRAS-G4 | BER-KRAS-G4 | COP-KRAS-G4 |
|----------------------|---------|-------------|-------------|
| **NOE-Based Distance Restraints** |         |             |             |
| Total                | 745     | 728         | 686         |
| Intra-residue        | 516     | 446         | 432         |
| Inter-residue        |         |             |             |
| Sequential           | 156     | 185         | 163         |
| Long-range           | 73      | 60          | 54          |
| Ligand-G4            | -       | 37          | 37          |
| **Other restraints** |         |             |             |
| Hydrogen bonds       | 48      | 48          | 48          |
| Torsion angles       | 24      | 24          | 24          |
| G-tetrad planarity   | 48      | 48          | 48          |
| **Structural statistics** |       |             |             |
| Pairwise heavy atom RMSD (Å) |       |             |             |
| G-tetrad core        | 0.58 ± 0.21 | 0.58 ± 0.17 | 0.49 ± 0.15 |
| All residues         | 0.71 ± 0.21 | 0.75 ± 0.16 | 0.64 ± 0.14 |
| **Restraint violations (Å)** |       |             |             |
| Max. NOE             | 0.12    | 0.14        | 0.12        |
| Mean NOE             | 0.001 ± 0.006 | 0.002 ± 0.010 | 0.001 ± 0.008 |

**Fig. 4 | NMR solution structures of KRAS-G4 and its complexes with berberine and coptisine.** Superposition of the ten lowest energy NMR structures of the free KRAS-G4 (a), berberine-KRAS-G4 (b), and coptisine-KRAS-G4 (c) by NOE-restrained structure calculations. Yellow, berberine; green, coptisine; cyan, flanking guanine; gray, tetrad guanine; magenta, adenine; blue, thymine; orange, cytosine.
A similar H-bond has been previously reported in the complex of epiberberine to a telomeric G4. Moreover, solvent exchange experiments showed that the guanine imino protons in ligand-KRAS-G4 complex structures are significantly protected compared to free KRAS-G4, which could be attributed to the π-stacking, electrostatic, and/or H-bond interactions between the ligand and KRAS-G4 (Supplementary Fig. 35). Interestingly, the 4-nt loop structure is not involved in the binding pocket formation in both the berberine-Pu24m1 and coptisine-Pu24m1 complexes (Figs. 4 and 5).

Berberine and coptisine stalled the replication of wild-type KRAS-G4 containing DNA fragment

To investigate if berberine and coptisine can stabilize the KRAS-G4 in the extended DNA context, we performed a DNA polymerase stop assay using a DNA template that contains the wild-type KRAS-G4 forming motif. The formation of KRAS-G4 in the template DNA was confirmed by the 1D 1H NMR experiment, as imino protons that characterized G4 structures were shown at 10–12 ppm (Supplementary Fig. 36). The G4 secondary structure formation in the template strand can block the Taq DNA polymerase from synthesizing the complementary strand DNA. As shown in Fig. 7a, a premature product (stalled product) was observed faintly in the 50 mM K+-containing reactions, indicating KRAS-G4 formation. Notably, the addition of berberine and coptisine significantly blocked the Taq DNA polymerase in a dose-dependent manner, as shown by the increasing amount of the stalled product in the 50 mM K+-containing solutions. The results suggest that berberine and coptisine may be able to stabilize the physiological relevant KRAS-G4 and therefore affect the function of KRAS-G4 in cells, such as replication and transcription regulation.

Berberine and coptisine significantly lowered KRAS oncogene transcription levels in cancer cells

The stabilization of G4 in the KRAS oncogene promoter was found to lower KRAS gene transcription levels. To determine the effect of berberine and coptisine on the KRAS transcription levels, a quantitative reverse transcription PCR (qRT-PCR) experiment was performed on non-small cell lung cancer cells (H460 and A549) which harbor KRAS mutations with unfavorable therapeutic outcomes, and normal human bronchial epithelial cells (BEAS-2B). The IC50 values of berberine and coptisine toward these three cell lines were first determined (Supplementary Fig. 37). Subsequently, H460, A549, and BEAS-2B cells were incubated with berberine and coptisine for 24 h and 48 h, respectively, and the KRAS mRNA levels were then measured. The results showed that berberine and coptisine significantly lowered the KRAS mRNA levels in the two cancer cell lines, while not in the normal BEAS-2B cells (Fig. 7b and Supplementary Figs. 38 and 39). Furthermore, the colonies formation numbers were significantly decreased in the berberine and coptisine treatment A549 and H460 groups, but not in BEAS-2B cell lines (Supplementary Fig. 40). Collectively, these results indicated that coptisine and berberine could inhibit the KRAS oncogene transcription levels and the proliferation of the cancer cells, suggesting they are promising KRAS-G4 targeting drugs.
Designing new berberine and coptisine derivatives with enhanced selectivity and/or affinity for KRAS-G4

Although berberine and coptisine show promising KRAS-G4-targeting therapeutic potential, there is space for chemical modifications to achieve enhanced selectivity and/or affinity (Figs. 1b, 8, and Supplementary Fig. 41). Firstly, the 9- and 10-OMe group of berberine or the methylenedioxy ring F of coptisine can be modified with a functional side chain for specific 4-nt long loop and groove interactions. Secondly, the methylenedioxy ring E of berberine and coptisine are the sites to introduce the second side chains for groove interactions. Lastly, but most importantly, the H1, H12, and H13 of berberine and coptisine toward the bulging thymine T10, which can be used to introduce specific H-bond interactions. Collectively, new berberine and coptisine derivatives can be designed by introducing distinct side chains or judicious chemical modifications to achieve enhanced selectivity and/or affinity for KRAS-G4.

Discussion

Although several types of free KRAS-G4 structures and some KRAS-G4–interactive small molecules have been reported, to date, no available KRAS–G4–ligand complex structure has yet been determined, which seriously hinders the structure-based rational design of KRAS-G4 specific drugs. Herein, we determined the NMR solution structures of the bulge-containing KRAS-G4 bound to two natural isoquinoline alkaloids, berberine, and coptisine, respectively. The determined complex structure shows a 2:1 binding stoichiometry with each berberine or coptisine recruits the adjacent flanking adenine residue to form a “quasi-triad plane” that stacks over the two external G-tetrads, which is similar to the recently determined complex structures of berberine bound to a MYC-G4 or a dGMP-fil-in PDGFR-β vacancy G4 Ref. The binding involves both π-stacking and electrostatic interactions, and further enhancing affinity and selectivity of berberine and coptisine derivatives to the KRAS-G4 are proposed by introducing additional side chains or specific hydrogen bonds. Moreover, berberine and coptisine significantly stall the Taq DNA polymerase synthesis of DNAs and lower the KRAS mRNA levels in cancer cells. Notably, target specificity of the two compounds appears to be weak and an in-depth structure–activity–relationship (SAR) analysis based on the determined high-resolution complex structures is highly required. Collectively, our study contributes structural insights into the ligand interactions with KRAS-G4 and provides a model system for the design of specific KRAS-G4–interactive small molecules.

Methods

Sample preparation

Labeled and unlabeled DNA oligonucleotides were obtained from Sangon Biotech (Shanghai, China) Co., Ltd. The DNA was dissolved in a buffer containing 37.5 mM KCl, 12.5 mM K2HPO4/KH2PO4, pH 7.10/90% D2O/H2O. The DNA concentrations were quantified by a UV spectrometer using the extinction coefficients. Berberine and coptisine were purchased from Shanghai Standard Technology Co., Ltd., which were dissolved in DMSO-d6 to a stock solution of 40 mM.
Nuclear magnetic resonance (NMR) spectroscopy experiments

1D and 2D NMR data were collected on a Bruker AV-600 spectrometer (QCI cryoprobe). The 95% water suppression was used. 2D NOESY were collected at temperatures of 20, 25, and 35 °C with mixing times of 80, 150, 300, and 500 ms in 90% H2O/10% D2O solutions. Moreover, some representative NOE build-up curves have been determined (Supplementary Fig. 42). The NOE distance calibration was done using the cytosine H5/H6 distance (2.4 Å). DQF-COSY spectrum was collected at 25 °C. 1H-13C HSQC spectra were collected using the hsqcetgpsi pulse experiment data for the berberine-DNA and coptisine-DNA complexes, respectively. Exchangeable protons were defined as very weak (6.0 ± 1.5 Å), weak (5.0 ± 1.5 Å), and medium (4.0 ± 1.5 Å). Overlapped and ambiguous resonances were defined as a distance of 5.0 ± 1.5 Å. Dihedral restraints of 170°–280° and 200°–310° were used for anti-conformations in the loop and within the G-tetrad, respectively.

NOE-restrained molecular dynamics refinement

NOE-restrained molecular dynamics refinement was carried out as previously described. The 20 lowest-energy structures from the simulated-annealing process were solvated with TIP3P water and neutralized with K⁺ cations, including two K⁺ in between the three G-tetrad. The system was then equilibrated and minimized by fixing the DNA position with 25 kcal mol⁻¹ Å⁻² force constants. Subsequently, the system was heated in 20 ps from 100 to 300 K with constant volume, while the DNA force constant was decreased gradually from 5, 4, 3, 2, 1 to 0.5 kcal mol⁻¹ Å⁻² in each 10 ps. The final 4 ns production run was conducted in the Amber pmemd module with constant pressure and snapshots were taken at each 1 ps. Force constants of 25, 10, and 5 kcal mol⁻¹ Å⁻² for hydrogen bond, NOE-based distance, and G-tetrad

Fig. 7 | Functional characterization of KRAS-G4. a Taq DNA polymerase stop assay using a DNA template containing a wt human KRAS-G4 forming sequence shows that berberine and coptisine can stabilize the KRAS-G4 for replication inhibition. b qRT-PCR results show that berberine (24 μM) and coptisine (10 μM) lower KRAS mRNA levels in both H460 and A549 cancer cells for 24 h. DMSO (<0.1%) was used as the negative control (no inhibition, 100%). The relative KRAS mRNA levels were normalized with GAPDH. The experiments were run in triplicate. Data are presented as mean values ± SD. P values (*P < 0.01, **P < 0.001, ***P < 0.0001) were determined by one-way ANOVA with post hoc Dunnett, relative to DMSO control.

Fig. 8 | Suggested modifications of berberine enabling additional interaction with the KRAS-G4. The black circles indicate the positions to be modified by introducing side chains for groove interactions. The black arrows show the grooves at 5’- and 3’-sites where the attached side chain will locate. The red circle suggests the positions to introduce hydrogen bonds between berberine and thymine T10. The KRAS-G4 is shown in cartoon representation. Cyan, guanine; magenta, adenine; blue, thymine; orange, cytosine; yellow, berberine.
planarity restraints were employed, respectively. Without G-tetrad planarity restraints, similar final structures were obtained. Supplementary Fig. 43). Finally, the last 500 ps of the trajectories were averaged and energy-minimized for 500 steps in the vacuum after removal of the water molecules and cations. Final ensemble and deposition were conducted using the ten lowest energy structures. The VMD and PyMOL software were used for analysis and visualization.24,73

Circular Dichroism (CD) experiments
CD data were collected on a Jasco-1500 spectropolarimeter (Jasco Inc., Japan). 20 μM DNA samples were prepared in a buffer containing 3.5 mM K2HPO4/KH2PO4, 11.5 mM KCl, pH 7. The DNA samples were annealed before use. Berberine or coptisine were added in the desired concentrations. CD spectra were collected using a 1 mm path length quartz cuvette at 25 °C. The blank correction was applied. For CD melting, the sample was heated from 25 to 95 °C with a heating rate of 2 °C/min, and the CD ellipticity at 264 nm was recorded. The melting temperature was then obtained at the intersection between the median of the fitted baselines and the melting curve.

Fluorescence measurements
Fluorescence data were collected on a Jasco-FP8300 spectrofluorometer (Jasco Inc., Japan). Fluorescence spectra were acquired in a 1 cm path length quartz cell for the emission spectra from 520 to 600 nm. The excitation wavelength was set to 377 nm. The berberine or coptisine concentrations were fixed to 0.2 μM in a 50 mM K+ containing solution. Fluorescence data were collected after 2 min incubation at each time. The \( K_d \) value was obtained by fitting the data to an equation using GraphPad Prism software, with a 2:1 binding stoichiometry: \[ F = F_{\text{max}} + [\text{ligand}] \times K_d + (K_d + [\text{ligand}])^{-1} \times (F_{\text{max}} - F_0). \] Fluorescence-induced fluorescence intensity; \( F_0 \), ligand concentration; \( F_{\text{max}} \), complex concentration.

DNA polymerase stop assay
This assay was performed as previously described.24 The 5′-end FAM labeled primer (5′-FAM-TAATACGACTCACTATAGCAATTGC) was mixed with template DNA in a 1:2.1 equivalent (5′-TGATCCTCTAGAGCAATTTCTGG3′). The mixtures were annealed by heating to 95 °C for 5 min then cooling to room temperature. Berberine and coptisine were added at various concentrations and incubated at room temperature for 3 hours. Primer extension was performed for 30 min in a 50 μL reaction buffer containing 0.2 μM DNA mixtures, 0.1 mM dNTP, 1.25 U/μL Taq DNA polymerase, 50 mM K+ (pH 7.0), and 2 mM MgCl2. The DNA products were resolved on a 12% denaturing polyacrylamide gel. DNA fragments were visualized by scanning on a ChemiDoc XRS + system (BIO-RAD, USA) and processed by Image Lab 6.1.

Native electrophoretic mobility shift assay (EMSA)
EMSA gel data were collected using a 1.5 mm thick 10 × 7 cm native gel, which contained 12.5 mM KCl and 16% acrylamide, pH 8.0. DNA samples, in the absence and presence of berberine and coptisine, were prepared in a 37.5 mM KCl, 12.5 mM phosphate buffer, pH 7.0. DNA bands were visualized at 260 nm under UV light.

Cell viability assay
Cells were grown in the RPMI 1640 medium supplemented with 10% FBS (Gibco, USA) and 1% Penicillin–Streptomycin Solution at 37 °C in a humidified atmosphere of 95% air and 5% CO2. Cells were seeded in a 96-well plate at a concentration of 1.0–2.0 × 104 cells/well and treated with different gradient concentrations of coptisine and berberine maintained at 37 °C for 48 or 72 h. The cells were then treated with WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulphophenyl)-2H-tetrazolium, monosodium salt (MedChemExpress, Monmouth Junction, NJ, USA) for 3 h at 37 °C. The absorbance at 450 nm was determined with a microplate reader. The IC50 values were determined from the sigmoidal dose–response curves using GraphPad Prism.

Colon formation assay
Cells were seeded in 6-well plates containing a complete growth medium overnight and then treated with DMSO (<1%), 10 μM coptisine, or 24 μM berberine for 24 h. After 24 h, the medium was removed and replaced with fresh medium for 7–8 days. The cells were then washed with PBS and fixed with a 4% paraformaldehyde fix solution (Servicebio, China) for 10 min. Subsequently, the cells were stained with crystal violet staining solution (Beyotime, China) for 10 min. Finally, the plates were washed, dried, and photographed.

Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was collected using the RNA extraction kit (Yishan Bio., China) according to the manufacturer’s instructions. RNA was reverse transcribed using the HiScript Q RT SuperMix kit (Vazyme, China). qRT-PCR was performed using Lightcycler 480 (Roche, Germany). SYBR Green Real-Time PCR Master Mix (Vazyme, China) was selected as the amplification reagent. GAPDH was used as an endogenous control. ΔΔCt method was used to analyze the mRNA levels and each experiment was performed in independent triplicates. The

KRAS primer. F: 5′-CAGTAGACACAAAAACAGGCTCAG-3′
R: 5′-TGTCGGATCTCCCTACCAATG-3′

GAPDH primer. F: 5′-GGTGAAGGTCGGATCAACGG-3′
R: 5′-GAGGCTAATGAAGGCTCATTG-3′

Statistical analysis
All experiments were run in 2–3 independent replicates. Statistical significance of differences between groups was analyzed using one-way ANOVA with post hoc Dunnett, relative to the control (**\( P < 0.01 \), ***\( P < 0.001 \), ****\( P < 0.0001 \)).

Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
Source data are provided in this paper. The data that support the findings of this study are available from the corresponding authors upon reasonable request. The coordinates and experimental details generated in this study have been deposited in the Protein Data bank under accession codes 7X8N (free KRAS-G4), 7X8M (2:1 berberine–KRAS-G4 complexes), and 7X8O (2:1 coptisine–KRAS-G4 complexes).

References
1. Moore, A. R., Rosenberg, S. C., McCormick, F. & Malek, S. RAS-targeted therapies: is the undruggable drugged? Nat. Rev. Drug Discov. 19, 533–552 (2020).
2. Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).
3. Reck, M., Carbone, D. P., Garassino, M. & Barlesi, F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann. Oncol. 32, 1101–1110 (2021).
4. Kim, D., Xue, J. Y. & Lito, P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients. Cell 183, 850–859 (2020).
5. Chen, K., Zhang, Y., Qian, L. & Wang, P. Emerging strategies to target RAS signaling in human cancer therapy. J. Hematol. Oncol. **14**, 116 (2021).

6. Nagasaka, M. et al. KRAS inhibitors—yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond. Cancer Treat. Rev. **101**, 102309 (2021).

7. Ostrom, J. M., Penning, U., Soos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature **503**, 548–551 (2013).

8. Skoulidis, F. et al. Sotaxabib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. **384**, 2371–2381 (2021).

9. Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature **575**, 217–223 (2019).

10. Awad, M. M. et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med. **384**, 2382–2393 (2021).

11. Zaborszky, L. et al. Promoter G-quadruplexes and transcription factors cooperate to shape the cell type-specific transcriptome. Nat. Commun. **12**, 3885 (2021).

12. Wang, E., Thombre, R., Shah, Y., Latanich, R. & Wang, J. G-Quadruplexes as pathogenic drivers in neurodegenerative disorders. Nucleic Acids Res. **49**, 4816–4830 (2021).

13. Zhang, X., Spiegel, J., Martinez Cuesta, S., Adhikari, S. & Balasubramanian, S. Chemical profiling of DNA G-quadruplex-interacting proteins in live cells. Nat. Chem. **13**, 626–633 (2021).

14. King, J. J. et al. DNA G-quadruplex and i-Motif structure formation is interdependent in human cells. J. Am. Chem. Soc. **142**, 20600–20604 (2020).

15. Dai, Y., Peng, X. & Li, J. Single-cell visualization of monogenic RNA G-quadruplex and occupied G-quadruplex ratio through module assembled multifunctional probes assay (MAMPA). Angew. Chem. Int. Ed. **61**, e202111132 (2021).

16. Liu, L. Y. et al. Quantitative detection of G-quadruplex DNA in live cells based on photon counts and complex structure discrimination. Angew. Chem. Int. Ed. **59**, 9719–9726 (2020).

17. Summers, P. A. et al. Visualising G-quadruplex DNA dynamics in live cells by fluorescence lifetime imaging microscopy. Nat. Commun. **12**, 162 (2021).

18. Siddiqui-Jain, A., Grand, C. L., Bearss, D. J. & Hurley, L. H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA **99**, 11593–11598 (2002).

19. Cogoi, S. & Xodo, L. E. G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res. **34**, 2536–2549 (2006).

20. Dickerhoff, J., Dai, J. & Yang, D. Structural recognition of the MYC promoter G-quadruplex by a quinoline derivative; insights into molecular targeting of parallel G-quadruplexes. Nucleic Acids Res. **49**, 5905–5915 (2021).

21. Zhu, B. C. et al. Selectivity and targeting of G-quadruplex binders activated by adaptive binding and controlled by chemical kinetics. Angew. Chem. Int. Ed. **60**, 15340–15343 (2021).

22. Liu, W. et al. Solution structures of multiple G-quadruplex complexes induced by a platinum(II)-based tripod reveal dynamic binding. Nat. Commun. **9**, 4396 (2018).

23. Cogoi, S., Paramasivam, M., Spolaore, B. & Xodo, L. E. Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins. Nucleic Acids Res. **36**, 3765–3780 (2008).

24. Amato, J. et al. HMGB1 binds to the KRAS promoter G-quadruplex: a new player in oncogene transcriptional regulation? Chem. Commun. **54**, 9442–9445 (2018).

25. Cogoi, S., Ferrero, A., Miglietta, G., Pedersen, E. B. & Xodo, L. E. The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription. Nucleic Acids Res. **46**, 661–676 (2018).

26. Cogoi, S., Rapozi, V., Cauvi, S. & Xodo, L. E. Critical role of hNRNP A1 in activating KRAS transcription in pancreatic cancer cells: a molecular mechanism involving G4 DNA. Biochim. Biophys. Acta. Genev. **1861**, 1399–1447 (2017).

27. Wen, L. N. & Xie, M. X. Spectroscopic investigation of the interaction between G-quadruplex of KRAS promoter sequence and three isoquinoline alkaloids. Spectrochem. Acta Part A Mol. Biomol. Spectrosc. **171**, 287–296 (2017).

28. Pattanayak, R., Basak, P., Sen, S. & Bhattacharyya, M. Interaction of KRAS G-quadruplex with natural polyphenols: A spectroscopic analysis with molecular modeling. Int. J. Biol. Macromolecules **89**, 228–237 (2016).

29. Lavrado, J. et al. KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. Sci. Rep. **5**, 9696 (2015).

30. Paramasivam, M., Cogoi, S. & Xodo, L. E. Primer extension reactions as a tool to uncover folding motifs within complex G-rich sequences: analysis of the human KRAS NHE. Chem. Commun. **47**, 4965–4967 (2011).

31. Kaiser, C. E. et al. Insight into the complexity of the i-Motif and G-quadruplex DNA structures formed in the KRAS promoter and subsequent drug-induced gene repression. J. Am. Chem. Soc. **139**, 8522–8536 (2017).

32. Kerkour, A. et al. High-resolution three-dimensional NMR structure of the KRAS proto-oncogene promoter reveals key features of a G-quadruplex involved in transcriptional regulation. J. Biol. Chem. **292**, 8082–8091 (2017).

33. Marquevielle, J. et al. Structure of two G-quadruplexes in equilibrium in the KRAS promoter. Nucleic Acids Res. **48**, 9336–9345 (2020).

34. Ou, A. et al. High-resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A stacking interactions for small-molecule recognition. Nucleic Acids Res. **48**, 5766–5776 (2020).

35. Atanasov, A. G., Zotchov, S. B., Dirsch, V. M. & Supuran, C. T. Natural products in drug discovery: advances and opportunities. Nat. Rev. Drug Discov. **20**, 200–216 (2021).

36. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. **83**, 770–803 (2020).
46. Wang, K. B. et al. Indenoisoquinoline topoisomerase inhibitors strongly bind and stabilize the MYC P promoter G-quadruplex and downregulate MYC. J. Am. Chem. Soc. 141, 11059–11070 (2019).

47. Wang, K. B., Dickerhoff, J. & Yang, D. Solution structure of ternary complex of berberine bound to a dGMP-fill-in vacancy G-quadruplex formed in the PDGFR-β promoter. J. Am. Chem. Soc. 143, 18649–18655 (2021).

48. Wang, K. B. et al. A series of β-carboline alkaloids from the seeds of Peganum harmala show G-quadruplex interactions. Org. Lett. 18, 3398–3401 (2016).

49. Lin, C. et al. Molecular recognition of the hybrid-2 human telomeric G-quadruplex by epiberberine: insights into conversion of telomeric G-quadruplex structures. Angew. Chem. Int. Ed. 57, 10888–10893 (2018).

50. Dickerhoff, J., Brundridge, N., McLuckey, S. A. & Yang, D. Berberine molecular recognition of the parallel MYC G-quadruplex in solution. J. Med. Chem. 64, 16205–16212 (2021).

51. Jana, J. & Weisz, K. A thermodynamic perspective on potential G-quadruplex structures as silencer elements in the MYC promoter. Chemistry 26, 17242–17251 (2020).

52. Bielskutė, S., Plavec, J. & Podbevšek, P. Oxidative lesions modulate G-quadruplex stability and structure in the human BCL2 promoter. Nucleic Acids Res. 49, 2346–2356 (2021).

53. Chen, J. et al. The beginning and the end: flanking nucleotides induce a parallel G-quadruplex topology. Nucleic Acids Res. 49, 9548–9559 (2021).

54. Wu, G. et al. Custom G4 microarrays reveal selective G-quadruplex recognition of small molecule MVBC: a large-scale assessment of ligand binding selectivity. Molecules 25, 3465 (2020).

55. Del Villar-Guerra, R., Trent, J. O. & Chaires, J. B. G-quadruplex secondary structure obtained from circular dichroism spectroscopy. Angew. Chem. Int. Ed. 56, 7171–7175 (2018).

56. Kotar, A. et al. Structure of a triangulinated-based long-lived fluorescence probe bound to a G-quadruplex. Angew. Chem. Int. Ed. 55, 12508–12511 (2016).

57. Agrawal, P., Hatzakis, E., Guo, K., Carver, M. & Yang, D. Solution structure of the major G-quadruplex formed in the human VEGF promoter in K+: insights into loop interactions of the parallel G-quadruplexes. Nucleic Acids Res. 41, 10584–10592 (2013).

58. Arévalo-Ruiz, M. et al. Synthesis, binding properties, and differences in cell uptake of G-quadruplex ligands based on carbohydrate naphthalene diimide conjugates. Chemistry 23, 2157–2164 (2017).

59. Lin, C., Dickerhoff, J. & Yang, D. NMR studies of G-quadruplex structures and G-quadruplex–interactive compounds. Methods Mol. Biol. 2035, 257–274 (2019).

60. Liu, W. et al. Structures of 1:1 and 2:1 complexes of BMVC and MYC promoter G-quadruplex reveal a mechanism of ligand conformation adjustment for G4-recognition. Nucleic Acids Res. 47, 11931–11942 (2019).

61. Dai, J., Carver, M., Hurley, L. H. & Yang, D. Solution structure of a 2:1 quinoline-c-MYC G-quadruplex: insights into G-quadruplex–interactive small molecule drug design. J. Am. Chem. Soc. 133, 17673–17680 (2011).

62. Calabrese, D. R. et al. Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex. Nat. Commun. 9, 4229 (2018).

63. Takahashi, S. et al. Chemical modulation of DNA replication along G-quadruplex based on topology-dependent ligand binding. J. Am. Chem. Soc. 143, 16458–16469 (2021).

64. Yan, H. et al. MiR-1205 functions as a tumor suppressor by disconnecting the synergy between KRAS and MDM4/E2F1 in non-small cell lung cancer. Am. J. Cancer Res. 9, 312–329 (2019).

65. Dickerhoff, J., Onel, B., Chen, L., Chen, Y. & Yang, D. Solution structure of a MYC promoter G-quadruplex with 1:6:1 loop length. ACS Omega 4, 2533–2539 (2019).

66. Schwieters, C. D., Kuszewski, J. J., Tjandra, N. & Clore, G. M. The Xplor-NIH NMR molecular structure determination package. J. Magn. Reson. 160, 65–73 (2003).

67. Frisch, M. J. T. et al. gaussian 09, Revision d. 01, Gaussian. Inc., Wallingford CT (2009).

68. Case D. A. et al. AMBER 2020, University of California, San Francisco, (2020).

69. Krepl, M. et al. Reference simulations of noncanonical nucleic acids with different y variants of the AMBER force field: G-quadruplex DNA, quadruplex RNA, and Z-DNA. J. Chem. Theory Comput. 8, 2506–2520 (2012).

70. Zgarbóvá, M. et al. Toward improved description of DNA backbone: revisiting epsilon and zeta torsion field parameters. J. Chem. Theory Comput. 9, 2339–2354 (2013).

71. Zgarbóvá, M. et al. Refinement of the sugar–phosphate backbone torsion beta for AMBER force fields improves the description of Z-and B-DNA. J. Chem. Theory Comput. 11, 5723–5736 (2015).

72. Schrödinger, L. The PyMOL molecular graphics system, version 2.1. (2018).

73. Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38 (1996).

74. Takahashi, S. & Sugimoto, N. Quantitative analysis of stall of replicating DNA polymerase by G-quadruplex formation. Methods Mol. Biol. 2035, 257–274 (2019).

Acknowledgements
This research was supported by the National Natural Science Foundation of China (K.W., 81773886 and L.K., 82173707), the Program for Jiangsu Province Innovative Research Scholar (K.W., 1402100013), the Natural Science Foundation of Jiangsu Province (K.W., BK20210420), the Scientific Research Foundation of Nanjing for Returned Chinese Scholar (K.W., No. 1412100026), and the Scientific Research Foundation for high-level faculty, China Pharmaceutical University, Nanjing, China (K.W., No. 3150020065). We thank Prof. Dr. Dazhou Yang and Dr. Jonathan Dickerhoff at Purdue University (USA) for their comments and for proofreading the manuscript.

Author contributions
K.W. and L.K. conceptualized and designed the experiments. K.W., Y.X., T.Y., and M.Y. supervised the study. K.W. and L.K. performed most of the experiments with J.L., C.X., Y.W., W.G., and Y.L. as assistants. K.W., Y.L., and L.K. wrote the manuscript. All authors have read and approved the final version of the manuscript.

Competing interests
The authors declare no Competing interests.
